This browser does not support the Video element.
President Joe Biden announced that the federal government would for the first time start mailing 500 million free rapid tests directly to Americans in January.
Johnson & Johnson’s COVID-19 booster shot was found to offer strong protection against the omicron variant, reducing the risk of hospitalization by about 85%, according to a clinical trial in South Africa.
The findings come at a critical point as COVID-19 cases from omicron are surging around the world. The World Health Organization said cases increased by 11% last week compared with the previous week, with the biggest increase in the Americas. Reported new cases in Africa were up 7% to nearly 275,000.
The study compared more than 69,000 boosted health care workers in South Africa who previously received the one-dose J&J shot, compared to unvaccinated participants. The booster shot was found to prevent 63% of hospitalizations within two weeks after receiving the jab, and increased to 85% effectiveness within one to two months after the booster.
FILE - A healthcare worker administers the Johnson and Johnson vaccine to a woman outside a polling station in Laudium, Pretoria, on Nov. 1, 2021, during South Africa's local elections. (Photo by PHILL MAGAKOE/AFP via Getty Images)
The trial was conducted by the South African Medical Research Council between Nov. 8 to Dec. 17, when omicron became the dominant variant and quickly spread throughout the country.
The results were published Wednesday in a preprint server and have not been peer-reviewed.
U.S. health regulators have authorized the J&J vaccine as a booster shot, but the U.S. Centers for Disease Control and Prevention says other booster shots by Pfizer-BioNTech or Moderna are preferred in most situations — citing the risk of rare yet life-threatening blood clots linked to the J&J shot.
This is a developing story. Check back for updates.